coadministered cagrilintide and semaglutide in adults with overweight or obesity the REDEFINE 2 phase 3a trial involving diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide–Semaglutide in Adults with Overweight
Pay in 4 interest-free payments of $7.19 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5

























